HFCL Wins ₹2,666 Cr BharatNet Deal; Lupin Launches US Hypertension Drug

HFCL has secured a significant ₹2,666.09 crore contract from Rail Vikas Nigam (RVNL) for the BharatNet Phase-III project. This development coincides with Lupin’s launch of its Azilsartan Medoxomil Tablets in the United States, targeting the adult hypertension market.

HFCL’s BharatNet Expansion

The contract awarded to HFCL by RVNL focuses on the Uttar Pradesh (West) Telecom Circle. This substantial deal underscores HFCL’s role in India’s digital infrastructure build-out.

• The contract value is approximately ₹2,666.09 crore.
• Scope includes telecom equipment supply, installation, commissioning, and creation of an Optical Fiber Cable Telecom Network.
• Project maintenance is covered for 10 years, including a 1-year warranty.
• This latest award follows an earlier ₹2,167.65 crore contract from RVNL for other BharatNet Phase-III projects.

Lupin Enters US Hypertension Market

Pharmaceutical major Lupin has launched a new drug in the United States, expanding its presence in the competitive US market. This move follows regulatory approval and positions Lupin for growth in the hypertension segment.

• Lupin launched Azilsartan Medoxomil Tablets, in 40mg and 80mg dosages.
• Approval was granted by the United States Food and Drug Administration (USFDA).
• The product is bioequivalent to Azurity Pharmaceuticals’ Edarbi and treats hypertension in adults.
• Lupin holds exclusive first-to-file status, providing 180-day generic drug exclusivity.
• The reference drug, Edarbi, had estimated annual sales of $53.5 million in the U.S. (IQVIA MAT APRIL 2026).